$DXR News

Dynamic announces April 2026 cash distributions for Dynamic Active ETFs and ETF Series

Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center

Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026

Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions

Daxor To Showcase New, Rapid, Portable Blood Volume Analyzer At ACC.26 Annual Scientific Session

Daxor Details Portable FDA-Cleared Blood Volume Analyzer, 'Razor-and-Blades' Kit Growth at iAccess Alpha

Daxor Corporation (DXR) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Prepared Remarks Transcript

Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress

Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share

Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee

Daxor Open New BVA Program At Healthcare Site In Southern Middle Tennessee

Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business

Daxor Intends To Transition Regulatory Reporting Framework Requirement from Investment Company Act of 1940 To Securities Exchange Act of 1934

Daxor Announces Transition To Securities Exchange Act Of 1934 Reporting Company

Daxor Corporation Announces $9 Million Registered Direct Offering

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit

Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA